医学
吉西他滨
培美曲塞
内科学
埃罗替尼
肿瘤科
胃肠病学
临床终点
临床研究阶段
不利影响
化疗
胆囊癌
进行性疾病
癌症
外科
顺铂
临床试验
表皮生长因子受体
作者
Sung Hee Lim,Jung Yong Hong,Joon Oh Park,YOUNG SUK PARK,Seung Tae Kim
出处
期刊:Anticancer Research
[International Institute of Anticancer Research (IIAR) Conferences 1997. Athens, Greece. Abstracts]
日期:2023-08-30
卷期号:43 (9): 4161-4167
被引量:3
标识
DOI:10.21873/anticanres.16607
摘要
BACKGROUND/AIM: No standard treatment is currently recommended for advanced biliary tract cancer (BTC) after first-line therapy with gemcitabine plus cisplatin. We aimed to evaluate the efficacy and safety of a pemetrexed and erlotinib combination in patients with BTC previously treated with gemcitabine. PATIENTS AND METHODS: intravenous infusion on day 1 for three weeks and erlotinib 100 mg daily until disease progression or unacceptable toxicity. The primary endpoint was the overall response rate (ORR). RESULTS: The study enrolled 20 patients with BTC, including 12 (60%) with intrahepatic cholangiocarcinoma (IHCC), 3 (15%) with extrahepatic cholangiocarcinoma (EHCC), and 5 (25%) with gallbladder cancer (GBC). The ORR was 5%, and the disease control rate (DCR) was 55%. As of the cutoff point of March 31, 2023, the median progression-free survival (PFS) was 2.3 months [95% confidence interval (CI)=0.00-4.74] and the median overall survival (OS) was 5.6 months (95%CI=2.28-8.87). Patients with EHCC showed longer PFS and OS compared to patients with IHCC or GBC, but the differences were not significant. A baseline CEA greater than the upper normal limit was the only significant prognostic factor for a worse OS rate. The only treatment-related adverse event (TRAE) with severity grade ≥3 was anemia (5%). CONCLUSION: Salvage chemotherapy with pemetrexed plus erlotinib was well-tolerated and showed marginal clinical activity in BTC patients after failure to gemcitabine-based chemotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI